Physician profile
Alan Wayne James
NPI 1215982368
$1,669.49
in general payments reported to CMS, 2019-2025
20 companies · $17.03 in 2025
The $17.03 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $18.99 · 2021: $43.06 · 2022: $645 · 2023: $707 · 2024: $113 · 2025: $17.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.63 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $537.62 | 2020-2025 | Tezspire, Breztri, Fasenra |
| Genzyme Corporation | $272.74 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $128.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.40 | 2023-2024 | Cuvitru, Hyqvia |
| Pfizer INC. | $109.84 | 2023-2024 | |
| Glaxosmithkline, LLC. | $82.81 | 2022-2023 | Nucala |
| Genentech USA, INC. | $62.25 | 2019-2024 | Xolair |
| Kaleo, INC. | $58.95 | 2023 | Auvi-Q |
| Shire North American Group INC | $44.60 | 2019 | |
| Bio Products Laboratory USA, INC. | $43.64 | 2022-2023 | Gammaplex, Coagadex |
| Octapharma USA, INC. | $41.60 | 2019-2023 | Cutaquig |
| Grifols USA, LLC | $33.95 | 2023 | Prolastin-C Liquid, Xembify |
| Biocryst US Sales Co., LLC | $24.70 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.81 | 2024 | Voquezna |
| Pharming Healthcare, INC. | $20.68 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.04 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Circassia INC. | $14.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.28 | 2023 | |
| Csl Behring | $12.71 | 2023 | Haegarda |
| Sanofi Pasteur INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.